WP2, D2.3: Personalized 11Carbon PET aided hadron therapy
To adapt the treatment plan according to PET response halfway through the course of hadron therapy, to investigate hypoxia tracers, fluorinated aminoacides or DNA synthesis markers and to validate PET for early response assessment.
Select most suitable PET tracers for adaptive hadron therapy and early response evaluation. New tracers will be investigated including hypoxia tracer (a non exhaustive list is: 18F-MISO, 18F-FAZA, 62Cu-ATSM) other fluorinated aminoacids (18F-FET, 18F-FACBC, etc.) or DNA synthesis markers (18-fluorothymidine). The tools developed for FLUKA will be verified at CNAO in a clinical scenario. Comparisons with the standard 12C treatment plans will be studied in terms of dose, biological effect and ß+-emitters distributions
Enrolment for PhD at
University of Pavia, Italy
CERN, Switzerland – 3 months – Monte-Carlo Fluka simulations on 11C ion implantation profile modelling
HUG, Switzerland – 3 months – PET imaging on small animals at the Institute of Translational Molecular Imaging (ITMI)